This webinar presents the underpinning mechanisms driving freeze thaw applications and their implications across varied drug product containment configurations and volumes. The links between controlled freezing rates, container design, and cellular outcomes are explored by science-based research approaches taken on by industry collaborators. The outputs will support the future development of cell therapy cryopreservation configurations and options proven through a science-based approach to supplier-side process development and driven by technologies and best practices present in the cell and gene industry.
Samuel Molina, PhD, Manager, R&D Applied Life Sciences, West Pharmaceutical Services
Sam is the Cell and Gene Therapy SME in the Applied Life Sciences & Technology Scouting R&D organization at West. He came to West with 8 years of hands-on knowledge in primary human cell manufacturing at both academic and commercial scale, having developed processes and products for the 3D human primary cell models and immunology and cell therapy research markets
Peter Kilbride, PhD, Senior Scientist, CGT, Cytiva
Peter is Senior Scientist at Cytiva, with a focus on running cryopreservation related projects in the Cell and Gene Therapy space. After finishing his PhD in Mathematics and Low Temperature Biology from University College London, he joined Asymptote, later GE Healthcare and Cytiva setting up and running a dedicated cryobiological lab. He is responsible both for carrying out fundamental cryobiological work, but also developing academic-based processes into cGMP compliant workflows and running external collaborations.
An ISCT Process & Product Development Committee Webinar
Credit to the ISCT Process Development & Manufacturing Committee